A comparison of country-level data from the VISIONARY study examining treatment outcomes with preservative-free tafluprost/timolol fixed-dose combination therapy

Holló G, Kirwan J, Lopez-Lopez F, Zimina M, Fassari C, Oddone F; VISIONARY Study Group

2022
Current Medical Research and Opinion

Therapeutic Area

Glaucoma
Categories

Post-Approval studies/RWE

Affiliations

Tutkimusz Ltd., Solymár, Hungary; Eye Center, Prima Medica Health Centers, Budapest, Hungary; Queen Alexandra Hospital, Portsmouth Hospitals NHS Trust, Portsmouth, UK; Department of Ophthalmology, Instituto Oftalmologico Gomez-Ulla, Santiago de Compostela, Galicia, Spain; Department of Ophthalmology, LLC Vzglyad, Leningradskaya, Chita, Russia; Medical Affairs, Santen SA, Geneva, Switzerland; Glaucoma Unit, IRCSS-Fondazione Bietti, Rome, Italy

Related Publications

Metabolomic Profiling of Open-Angle Glaucoma Etiologic Endotypes: Tohoku Multi-Omics Glaucoma Study

Hanyuda A.; Raita Y.; Ninomiya T.; Hashimoto K.; Takada N.; Sato K.; Inoue J.; Koshiba S.; Tamiya G.; Narita A.; Akiyama M.; Omodaka K.; Tsuda S.; Yokoyama Y.; Himori N.; Yamamoto Y.; Taniguchi T.; Negishi K.; Nakazawa T.

Ocular Tissue Distribution of Omidenepag Isopropyl in Rabbits and Cynomolgus Monkeys

Yamamura K.; Mano H.; Fuwa M.; Ryoiwamura; Odani-Kawabata N.

Omidenepag Isopropyl 0.002% versus Latanoprost 0.005% in Open-Angle Glaucoma/Ocular Hypertension: The Randomized Phase III PEONY Trial

Wang T.H.; Aung T.; Lu D.-W.; George R.; Senthil S.; Lu F.; Odani-Kawabata N.; Park K.H.

View all Glaucoma publications